Safety and Efficacy analysis of 10 mg donepezil for severe Alzheimer's disease: switch from the other cholineseterase inhibitors

Safety and Efficacy analysis of 10 mg donepezil for severe Alzheimer's disease: switch from the other cholineseterase inhibitors - Switch to 10 mg donepezil for severe Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008971

Enrollment

Registered

2012-10-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Donepezil 10mg once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Alzheimer's disease patients who meet the criteria of DSM-IV-TR 2.MMSE score of 1-20 3.Severe AD patients who took Galantamine and Rivastigmine 4.The spouse or another caregiver has to accompany the patient.

Exclusion criteria

Exclusion criteria: 1.Patients with dementia except AD 2.Patients with high serum Vitamine level 3.Patients who are allergic to donepezil

Design outcomes

Primary

Measure	Time frame
Mini Mental state examination	—

Secondary

Measure	Time frame
Neuropsychiatric Inventory	—

Countries

Japan

Contacts

Public ContactYumiko Motoi

Juntendo University School of Medicine Department of Neurology

motoi@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Safety and Efficacy analysis of 10 mg donepezil for severe Alzheimer&#39;s disease: switch from the other cholineseterase inhibitors